194 related articles for article (PubMed ID: 37723153)
1. Network analysis of inflammation and symptoms in recent onset schizophrenia and the influence of minocycline during a clinical trial.
Herniman SE; Wood SJ; Khandaker G; Dazzan P; Pariante CM; Barnes NM; Krynicki CR; Nikkheslat N; Vincent RC; Roberts A; Giordano A; Watson A; Suckling J; Barnes TRE; Husain N; Jones PB; Joyce E; Lawrie SM; Lewis S; Deakin B; Upthegrove R;
Transl Psychiatry; 2023 Sep; 13(1):297. PubMed ID: 37723153
[TBL] [Abstract][Full Text] [Related]
2. Deconstructing depression and negative symptoms of schizophrenia; differential and longitudinal immune correlates, and response to minocycline treatment.
Krynicki CR; Dazzan P; Pariante CM; Barnes NM; Vincent RC; Roberts A; Giordano A; Watson A; Suckling J; Barnes TRE; Husain N; Jones PB; Joyce E; Lawrie SM; Lewis S; Deakin B; Upthegrove R;
Brain Behav Immun; 2021 Jan; 91():498-504. PubMed ID: 33161162
[TBL] [Abstract][Full Text] [Related]
3. The effect of minocycline on amelioration of cognitive deficits and pro-inflammatory cytokines levels in patients with schizophrenia.
Zhang L; Zheng H; Wu R; Kosten TR; Zhang XY; Zhao J
Schizophr Res; 2019 Oct; 212():92-98. PubMed ID: 31416745
[TBL] [Abstract][Full Text] [Related]
4. Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels.
Zhang L; Zheng H; Wu R; Zhu F; Kosten TR; Zhang XY; Zhao J
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jul; 85():69-76. PubMed ID: 29678772
[TBL] [Abstract][Full Text] [Related]
5. Alteration patterns of peripheral concentrations of cytokines and associated inflammatory proteins in acute and chronic stages of schizophrenia: a systematic review and network meta-analysis.
Halstead S; Siskind D; Amft M; Wagner E; Yakimov V; Shih-Jung Liu Z; Walder K; Warren N
Lancet Psychiatry; 2023 Apr; 10(4):260-271. PubMed ID: 36863384
[TBL] [Abstract][Full Text] [Related]
6. Depression trajectories and cytokines in schizophrenia spectrum disorders - A longitudinal observational study.
Hoprekstad GE; Kjelby E; Gjestad R; Fathian F; Larsen TK; Reitan SK; Rettenbacher M; Torsvik A; Skrede S; Johnsen E; Kroken RA
Schizophr Res; 2023 Feb; 252():77-87. PubMed ID: 36634451
[TBL] [Abstract][Full Text] [Related]
7. Minocycline prevents the development of depression-like behavior and hippocampal inflammation in a rat model of Alzheimer's disease.
Amani M; Shokouhi G; Salari AA
Psychopharmacology (Berl); 2019 Apr; 236(4):1281-1292. PubMed ID: 30515523
[TBL] [Abstract][Full Text] [Related]
8. Changes in plasma levels of nitric oxide metabolites and negative symptoms after 16-week minocycline treatment in patients with schizophrenia.
Liu F; Zhang B; Xie L; Ruan Y; Xu X; Zeng Y; Messina L; Zhao J; Fan X
Schizophr Res; 2018 Sep; 199():390-394. PubMed ID: 29526457
[TBL] [Abstract][Full Text] [Related]
9. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia.
Na KS; Jung HY; Kim YK
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():277-86. PubMed ID: 23123365
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapy with minocycline for schizophrenia (The MINOS Trial): study protocol for a double-blind randomized placebo-controlled trial.
Fekadu A; Mesfin M; Medhin G; Alem A; Teferra S; Gebre-Eyesus T; Seboxa T; Assefa A; Hussein J; Lemma MT; Borba C; Henderson DC; Hanlon C; Shibre T
Trials; 2013 Nov; 14():406. PubMed ID: 24279305
[TBL] [Abstract][Full Text] [Related]
11. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment.
Chaudhry IB; Hallak J; Husain N; Minhas F; Stirling J; Richardson P; Dursun S; Dunn G; Deakin B
J Psychopharmacol; 2012 Sep; 26(9):1185-93. PubMed ID: 22526685
[TBL] [Abstract][Full Text] [Related]
12. Association of baseline inflammatory markers and the development of negative symptoms in individuals at clinical high risk for psychosis.
Goldsmith DR; Haroon E; Miller AH; Addington J; Bearden C; Cadenhead K; Cannon T; Cornblatt B; Mathalon D; McGlashan T; Seidman L; Tsuang M; Woods SW; Walker EF; Perkins DO
Brain Behav Immun; 2019 Feb; 76():268-274. PubMed ID: 30496778
[TBL] [Abstract][Full Text] [Related]
13. Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial.
Ghanizadeh A; Dehbozorgi S; OmraniSigaroodi M; Rezaei Z
Recent Pat Inflamm Allergy Drug Discov; 2014; 8(3):211-5. PubMed ID: 25353174
[TBL] [Abstract][Full Text] [Related]
14. Minocycline and antipsychotics inhibit inflammatory responses in BV-2 microglia activated by LPS via regulating the MAPKs/ JAK-STAT signaling pathway.
Long Y; Wang Y; Shen Y; Huang J; Li Y; Wu R; Zhao J
BMC Psychiatry; 2023 Jul; 23(1):514. PubMed ID: 37464316
[TBL] [Abstract][Full Text] [Related]
15. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial.
Liu F; Guo X; Wu R; Ou J; Zheng Y; Zhang B; Xie L; Zhang L; Yang L; Yang S; Yang J; Ruan Y; Zeng Y; Xu X; Zhao J
Schizophr Res; 2014 Mar; 153(1-3):169-76. PubMed ID: 24503176
[TBL] [Abstract][Full Text] [Related]
16. Faster speed of onset of the depressive episode is associated with lower cytokine serum levels (IL-2, -4, -6, -10, TNF-α and IFN-γ) in patients with major depression.
Buspavanich P; Adli M; Himmerich H; Berger M; Busche M; Schlattmann P; Bopp S; Bschor T; Richter C; Steinacher B; Stoppel C; Hindinger C; Meyer S; Hoffmann K; Stamm T; Gabriel A; Merkl A; Goerke-Arndt F; Köhler S; Sterzer P; Heinz A; Behr J; Fakhri H; Lang F; Lang UE; Ricken R
J Psychiatr Res; 2021 Sep; 141():287-292. PubMed ID: 34271459
[TBL] [Abstract][Full Text] [Related]
17. Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables.
Lee EE; Hong S; Martin AS; Eyler LT; Jeste DV
Am J Geriatr Psychiatry; 2017 Jan; 25(1):50-61. PubMed ID: 27840055
[TBL] [Abstract][Full Text] [Related]
18. The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial.
Weiser M; Levi L; Burshtein S; Chiriță R; Cirjaliu D; Gonen I; Yolken R; Davidson M; Zamora D; Davis JM
Schizophr Res; 2019 Apr; 206():325-332. PubMed ID: 30455075
[TBL] [Abstract][Full Text] [Related]
19. Inflammation in first-episode psychosis: The contribution of inflammatory biomarkers to the emergence of negative symptoms, a systematic review and meta-analysis.
Dunleavy C; Elsworthy RJ; Upthegrove R; Wood SJ; Aldred S
Acta Psychiatr Scand; 2022 Jul; 146(1):6-20. PubMed ID: 35202480
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
